Trials / Completed
CompletedNCT06619678
A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016)
An Open-Label Study to Assess the Two-Way Interaction Between Multiple Weekly Doses of MK-8507 and Single Doses of Islatravir (MK-8591) in Healthy Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 19 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main goals of this study are to learn what happens to Islatravir or MK-8507 in a person's body over time. Researchers will compare Islatravir given alone to Islatravir given with MK-8507. Researchers will also compare MK-8507 given alone to MK-8507 given with Islatravir.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-8507 | Oral administration |
| DRUG | Islatravir | Oral administration |
Timeline
- Start date
- 2024-01-17
- Primary completion
- 2024-06-23
- Completion
- 2024-06-23
- First posted
- 2024-10-01
- Last updated
- 2024-10-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06619678. Inclusion in this directory is not an endorsement.